evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3 questions · 3 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria

It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal AST increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (very low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria

It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal AST increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (very low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artemether‐lumefantrine (AL)

First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) may leads to higher first treatment, abnormal AST increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).

1 finding from 1 review